Vanta Bioscience Ltd Quarterly Results
Q4 FY22-23 Results Summary
Revenue
The revenue stands at ₹0.63 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 77.66 per cent from ₹2.82 crore. This corresponds to a year-on-year *(YoY) decline of 0.00 per cent.
Operating Profit
Operating Profit stands at ₹-1.30 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 136.36 per cent from ₹-0.55 crore. This corresponds to a year-on-year *(YoY) decline of 0.00 per cent.
PBDT
PBDT stands at ₹-1.56 crore, reflecting a quarter-on-quarter *(QoQ) increase of 48.34 per cent from ₹-3.02 crore. This corresponds to a year-on-year *(YoY) decline of 0.00 per cent.
Profit Before Tax
Profit Before Tax stands at ₹-1.61 crore, reflecting a quarter-on-quarter *(QoQ) increase of 62.82 per cent from ₹-4.33 crore. This corresponds to a year-on-year *(YoY) decline of 0.00 per cent.
Net Profit
Net Profit stands at ₹-1.60 crore, reflecting a quarter-on-quarter *(QoQ) increase of 63.80 per cent from ₹-4.42 crore. This represents a 0.00 per cent year-on-year *(YoY) decline for the same year.
- YoY compares a quarter to the same period last year, and QoQ compares it to the previous quarter.
Market News
Vanta Bioscience Ltd Earnings
- YOY
- QOQ
Vanta Bioscience Ltd Earning Charts
Revenue from Operations
in ₹ cr
EBITDA
in ₹ cr
Profit before Tax
in ₹ cr
Net Profit
in ₹ cr
Vanta Bioscience Ltd Research Reports
| Action | Target Price (₹) | Broker | Date | Reports |
|---|---|---|---|---|
| Data Not Found | ||||
Vanta Bioscience Ltd Financial Reports
Vanta Bioscience Ltd Stock Prices Compare with Peers
| Company | 1 Day | 1 Week | 1 month | 3 month | 6 month | 1 Year |
|---|---|---|---|---|---|---|
| Transgene Biotek | 3.33% | -2.45% | -6.06% | -5.74% | 5.28% | -36.30% |
| Nexus Surgical | -2.93% | -6.02% | 70.62% | 65.50% | 83.38% | 74.21% |
| Global Longlife | -1.00% | 5.33% | 25.36% | 46.69% | -3.07% | -42.96% |
| Family Care | 0.00% | 0.00% | -0.99% | -38.08% | -30.56% | -53.49% |
| Looks Health | -4.69% | -5.94% | 3.78% | -11.64% | 16.90% | 75.56% |
| Dhanvantri Jeev. | -1.92% | -1.96% | -14.36% | 7.29% | 5.04% | -3.56% |
| Gian Lifecare | -2.95% | -3.56% | -6.12% | -9.80% | -33.91% | -71.23% |
Company Info
Company Information
Managing Director : Dopesh Raja Mulakala
Independent Non Exe. Director : Padmanabhuni Venkata Appaji
Independent Non Exe. Director : Kathyayani Gonuguntla
Independent Non Exe. Director : Yogeswara Rao Danda
Company Sec. & Compli. Officer : Pooja Kothari